Morgan Stanley initiated coverage of Arxis (ARXS) with an Overweight rating and $44 price target Arxis is a provider of proprietary, highly engineered components across defense, space, commercial aerospace, and specialized industrial, the analyst tells investors in a research note. The firm says the company’s organic growth and “compounder attributes” are not fully priced in at current share levels.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARXS:
- Arxis initiated with an Outperform at Baird
- Arxis initiated with a Buy at Goldman Sachs
- Arxis Initiated at Buy by Kristine Liwag on Durable Moat, Defense-Aerospace Tailwinds and Upside to $44 Price Target
- Goldman’s Poponak Initiates Arxis with Buy, Sees Significant Upside to $53 12‑Month Target on Defense-Weighted Growth Strategy
- Arxis Initiated at Buy: Industrial Compounder Model, Proprietary EDGE M&A Engine, and Premium-Valuation Upside to $55 Target